| This week's sponsor is Eli Lilly and Company. | |  | AHS 2018: Lilly Showcases Leadership in Migraine and Cluster Headache
For more than 50 years, Eli Lilly and Company has been committed to addressing the ongoing treatment challenges in neurology, primary headache disorders and chronic and recurrent pain. Learn more about Lilly's leadership in the development of innovative treatments for migraine and cluster headache here. |
Today's Rundown Featured Story | | | Wednesday, July 11, 2018 Adlai Noryte grabbed worldwide rights to Novartis' buparlisib, an oral PI3K inhibitor being developed for blood cancers and solid tumors that has run into toxicity issues. |
|
|
Top Stories Wednesday, July 11, 2018 Forbion has raised a €270 million ($316 million), Europe-focused life sciences fund. The bumper first close of the fund follows a period in which Forbion has shown a knack for picking winners. Wednesday, July 11, 2018 BioCryst Pharmaceuticals is once again left without a dance partner, after its shareholders voted down a proposal to merge with Idera Pharmaceuticals and form a combined rare disease company. Wednesday, July 11, 2018 A novel antifungal developed by Scynexis for the yeast infection vulvovaginal candidiasis has bested the current standard therapy in a midstage trial and is moving to a phase 3 program. Wednesday, July 11, 2018 AstraZeneca and 4D Molecular Therapeutics have joined forces to develop gene therapies against chronic lung diseases. The collaboration will use 4D’s adeno-associated virus vectors to create therapies that insert genes that code for therapeutic proteins into human cells. Tuesday, July 10, 2018 Cel-Sci has emerged victorious in what it describes as the first-ever decision in favor of a pharmaceutical company over a CRO for breach of contract, following a yearslong arbitration battle with inVentiv Health, now known as Syneos Health. Wednesday, July 11, 2018 Otsuka Pharmaceutical plans to acquire previous Fierce 15 winner Visterra and its antibody engineering platform for $430 million in cash. Otsuka is looking to build out proprietary drug discovery and development efforts across its programs, including in nephrology and other difficult diseases. Wednesday, July 11, 2018 With a tweet and a phone call, President Donald Trump convinced one of the giants in pharma to retreat on price increases, at least temporarily. The upshot? It’s not good news for other price-hiking drugmakers. | This week's sponsor is ExL Events. | | Can’t-miss interactive workshop at the industry's premier Safety Labeling & Packaging event!
This 3-day conference will provide attendees with the skills needed to understand how to develop & enhance an end-to-end process to ensure a compliant label for your drug packaging.
View the agenda and workshop details! Use Discount Code C1049FIERCE to save 15% |
Resources Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
